PMID- 22726922
OWN - NLM
STAT- MEDLINE
DCOM- 20121008
LR  - 20181201
IS  - 1873-5835 (Electronic)
IS  - 0145-2126 (Linking)
VI  - 36
IP  - 9
DP  - 2012 Sep
TI  - Extra copies of ALK gene locus is a recurrent genetic aberration and favorable 
      prognostic factor in both ALK-positive and ALK-negative anaplastic large cell 
      lymphomas.
PG  - 1141-6
LID - 10.1016/j.leukres.2012.06.005 [doi]
AB  - Systemic anaplastic large cell lymphoma (ALCL) is subtyped into ALK-positive ALCL 
      and ALK-negative ALCL based on the presence or absence of ALK protein expression. 
      ALK-positive ALCL is characterized by t(2;5)(p23;q35)/NPM-ALK or variant 
      ALK-involved translocations, while little is known about the genetic changes in 
      ALK-negative ALCL. We investigated the structural and numerical aberrations of 
      the ALK gene using interphase fluorescence in situ hybridization (FISH) in 81 
      cases with ALCL and analyzed their association with clinical outcome of the 
      patients. ALK gene rearrangement was found in 47 of 50 (94%) ALK-positive ALCLs 
      but in none of 31 ALK-negative ALCLs. Extra copies of the ALK gene locus, 
      representing mainly extra copies of chromosome 2, were seen in 19 ALK-positive 
      (38%) and 15 ALK-negative (48%) cases (P=0.357). In 55 cases with follow-up 
      information, the mean survival time of the 38 ALK positive cases (58 months) was 
      significantly longer than that of 17 ALK-negative cases (22.5 months) (P=0.038). 
      Interestingly, the cases with extra copies of ALK had a significantly longer mean 
      survival time than those without (64.4 months vs 35.3 months) (P=0.023) and this 
      difference was observed in both ALK-positive (72.3 vs 45.9 months) and 
      ALK-negative (34.7 vs 9.9 months) cases. Multivariate analysis showed that both 
      ALK protein expression and extra copies of ALK gene were independent predictors 
      for better survival (P=0.008). Our results suggest that the extra copies of ALK 
      gene locus are a frequent genetic aberration in both ALK-positive and 
      ALK-negative ALCL and is a favorable prognostic marker for the patients.
CI  - Copyright (c) 2012 Elsevier Ltd. All rights reserved.
FAU - Yu, Ran
AU  - Yu R
AD  - Department of Pathology, Basic Medical College, Capital Medical University, 
      Beijing, China.
FAU - Chen, Gang
AU  - Chen G
FAU - Zhou, Chunju
AU  - Zhou C
FAU - Gao, Zifen
AU  - Gao Z
FAU - Shi, Yunfei
AU  - Shi Y
FAU - Shi, Yan
AU  - Shi Y
FAU - Zhou, Xiaoge
AU  - Zhou X
FAU - Xie, Jianlan
AU  - Xie J
FAU - Liu, Hongxiang
AU  - Liu H
FAU - Gong, Liping
AU  - Gong L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120620
PL  - England
TA  - Leuk Res
JT  - Leukemia research
JID - 7706787
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anaplastic Lymphoma Kinase
MH  - Child
MH  - Child, Preschool
MH  - Cohort Studies
MH  - *DNA Copy Number Variations/genetics/physiology
MH  - Female
MH  - Gene Dosage
MH  - Gene Frequency
MH  - Genetic Loci
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Infant
MH  - Lymphoma, Large-Cell, Anaplastic/*diagnosis/*genetics
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Receptor Protein-Tyrosine Kinases/*genetics
MH  - Young Adult
EDAT- 2012/06/26 06:00
MHDA- 2012/10/09 06:00
CRDT- 2012/06/26 06:00
PHST- 2012/03/19 00:00 [received]
PHST- 2012/06/01 00:00 [revised]
PHST- 2012/06/03 00:00 [accepted]
PHST- 2012/06/26 06:00 [entrez]
PHST- 2012/06/26 06:00 [pubmed]
PHST- 2012/10/09 06:00 [medline]
AID - S0145-2126(12)00263-9 [pii]
AID - 10.1016/j.leukres.2012.06.005 [doi]
PST - ppublish
SO  - Leuk Res. 2012 Sep;36(9):1141-6. doi: 10.1016/j.leukres.2012.06.005. Epub 2012 
      Jun 20.